{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:49:02Z","timestamp":1776930542646,"version":"3.51.2"},"reference-count":15,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Obstet Med"],"abstract":"<jats:p>Dexamphetamine, a central nervous system stimulant, is increasingly prescribed to women of childbearing age, yet data on its safety in pregnancy, particularly for narcolepsy, remains limited. This case series examined pregnancy outcomes in 10 women with narcolepsy or idiopathic hypersomnolence at the Royal Brisbane and Women's Hospital who were prescribed dexamphetamine during pregnancy. Six women continued therapy throughout pregnancy. Apart from one case complicated by congenital CMV infection, all pregnancies progressed to the late third trimester with favourable neonatal outcomes. No cases of pre-eclampsia were observed; one woman developed gestational hypertension. All neonates had normal Apgar scores, with the exception of two where the Apgars were not recorded. However, no neonates required additional ventilatory support. Our findings suggest that therapeutic dexamphetamine use for narcolepsy may not be associated with adverse obstetric or neonatal outcomes. Individualised counselling is essential to balance maternal functional needs against potential pregnancy risks.<\/jats:p>","DOI":"10.1177\/1753495x261439640","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:36:09Z","timestamp":1776692169000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The use of dexamphetamine for narcolepsy during pregnancy: A case series and literature review"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1996-4778","authenticated-orcid":false,"given":"Katie","family":"Lane","sequence":"first","affiliation":[{"name":"Royal Brisbane and Women's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Steinbock","sequence":"additional","affiliation":[{"name":"Royal Brisbane and Women's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Carter","sequence":"additional","affiliation":[{"name":"Caboolture Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Lust","sequence":"additional","affiliation":[{"name":"Royal Brisbane and Women's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Maree","family":"Craven","sequence":"additional","affiliation":[{"name":"Royal Brisbane and Women's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3600"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6702a3"},{"key":"e_1_3_3_4_2","article-title":"Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy","volume":"2015","author":"Bro SP","unstructured":"Bro SP, Kjaersgaard MI, Parner ET, et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol 2015; 7: 139\u2013147.","journal-title":"Clin Epidemiol"},{"key":"e_1_3_3_5_2","first-page":"1192","article-title":"Placental complications associated with psychostimulant use in pregnancy","volume":"2017","author":"Cohen JM","unstructured":"Cohen JM, Hern\u00e1ndez-D\u00edaz S, Bateman BT, et al. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol 2017; 130: 1192\u20131201.","journal-title":"Obstet Gynecol"},{"key":"e_1_3_3_6_2","first-page":"377","article-title":"Perinatal outcomes of women diagnosed with attention-deficit\/hyperactivity disorder: an Australian population-based cohort study","volume":"2018","author":"Poulton AS","unstructured":"Poulton AS, Armstrong B, Nanan RK. Perinatal outcomes of women diagnosed with attention-deficit\/hyperactivity disorder: an Australian population-based cohort study. CNS Drugs 2018; 32: 377\u2013386.","journal-title":"CNS Drugs"},{"key":"e_1_3_3_7_2","first-page":"1295","article-title":"Amphetamine\u2013dextroamphetamine and pregnancy: neonatal outcomes after prenatal prescription mixed amphetamine exposure","volume":"2021","author":"Rose SJ","unstructured":"Rose SJ, Hathcock MA, White WM, et al. Amphetamine\u2013dextroamphetamine and pregnancy: neonatal outcomes after prenatal prescription mixed amphetamine exposure. J Atten Disord 2021; 25: 1295\u20131301.","journal-title":"J Atten Disord"},{"key":"e_1_3_3_8_2","first-page":"858","article-title":"Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995\u20132015","volume":"2016","author":"Renoux C","unstructured":"Renoux C, Shin J, Dell\u2019Aniello S, et al. Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995\u20132015. Br J Clin Pharmacol 2016; 82: 858\u2013868.","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12047"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.7966"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyac180"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3644"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-024-01450-4"},{"key":"e_1_3_3_14_2","first-page":"341","article-title":"Hospitalizations with amphetamine abuse among pregnant women","volume":"2008","author":"Cox S","unstructured":"Cox S, Posner SF, Kourtis AP, et al. Hospitalizations with amphetamine abuse among pregnant women. Obstet Gynecol 2008; 111: 341\u2013347.","journal-title":"Obstet Gynecol"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.903546"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.4294"}],"container-title":["Obstetric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753495X261439640","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1753495X261439640","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753495X261439640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:16:58Z","timestamp":1776928618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753495X261439640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":15,"alternative-id":["10.1177\/1753495X261439640"],"URL":"https:\/\/doi.org\/10.1177\/1753495x261439640","relation":{},"ISSN":["1753-495X","1753-4968"],"issn-type":[{"value":"1753-495X","type":"print"},{"value":"1753-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1753495X261439640"}}